Can a simpler, cheaper method for marking breast tumors work as well as ultrasound?
NCT ID NCT07716644
First seen Jul 21, 2026 · Last updated Jul 22, 2026 · Updated 1 time
Summary
This trial tests whether placing a small marker clip into a breast tumor without ultrasound guidance (using touch alone) is as accurate, safe, and cost-effective as using ultrasound. The study involves 50 women with palpable breast tumors who will receive neoadjuvant chemotherapy. The goal is to find a viable, lower-cost option for breast cancer care in low-resource settings.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- breast lesion clip placement (procedure)
- What this could lead to
- If blind clipping proves accurate and cost-effective, it could offer a practical alternative for breast cancer care in low-resource settings.
- What could go wrong
- This is a small, single-center trial, so results may not apply broadly. Blind clipping may be less accurate than ultrasound guidance.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
50 people
The number who actually took part.
- Started
-
Apr 2026
- Expected to finish
-
Jul 2026
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
25 to 75 years
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Female patients aged 25-75 years * Unifocal lesion * Palpable T1-T4 lesion * Planned Neoadjuvant chemotherapy (NACT) cases * Patient consent for tumor localization or breast-conserving surgery (BCS) Exclusion Criteria: * Known bleeding disorder * Inflammatory breast carcinoma * Multifocal or multicentric breast disease * Patients who do not consent for tumor localization or BCS
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Breast carcinoma are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Tertiary Care Hospitals, Faisalabad, Pakistan
Faisalābad, Punjab Province, 38000, Pakistan
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- AI-Assisted opportunistic breast cancer screening using non-contrast chest CT in women undergoing health examination: a retrospective validation and prospective Single-Arm interventional study
- Single-Fraction very accelerated partial breast irradiation (sfVAPBI) in Low-Risk invasive or ductal in situ breast carcinoma - phase II multicenter trial
- Could skipping a lymph node check spare women from unneeded surgery?
- Can exercise during breast cancer treatment boost fitness and predict response?
- Can a clotting drug cut mastectomy wound drainage?
- A simple dye might replace radioactive tracers in cancer staging